Clinical trials
Completed Observational Leukemia, Hairy Cell trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
14 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2012 | 2 |
| 2022 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 14 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Case Comprehensive Cancer Center | 2 |
| Children's Oncology Group | 2 |
| CHU de Reims | 1 |
| City of Hope Medical Center | 1 |
| Eastern Cooperative Oncology Group | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| HaEmek Medical Center, Israel | 1 |
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | 1 |
| Northwestern University | 1 |
| SWOG Cancer Research Network | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Hairy Cell | 14 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 11 |
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 10 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 10 |
| Leukemia | 9 |
| Leukemia, Myelomonocytic, Chronic | 9 |
| Blast Crisis | 8 |
| Congenital Abnormalities | 8 |
| Leukemia, Myeloid, Accelerated Phase | 8 |
| Leukemia, Myeloid, Acute | 8 |
Trials
Showing 1 to 14 of 14. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.